RNA Formulation Resources

1. Rethink Cell Therapy With LNPs 8/25/2025

   Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.

2. Low-Volume Production For Screening High-Value Nanoparticle Materials 4/18/2022

   A platform that harnesses microfluidic mixing has been demonstrated as a simple, robust, and scalable production method for LNPs encapsulating various types of nucleic acids.

3. Tangential Flow Filtration Of LNPs Results In 10X Concentration Within 20 Minutes 8/5/2025

   Dive into a study that details how a single-pass tangential flow filtration system can achieve a tenfold concentration of liposomal nanoparticles in under 20 minutes.

4. Accelerated Development Of Self-Amplifying mRNA (saRNA) Vaccines Using Microfluidics 4/14/2022

   We showcased the utility of microfluidics to enable low shear, rapid screening of preclinical candidates and the swift advancement to GMP-enabling studies.

5. Recommendations For Successful IND Approval Of RNA-LNP Drugs 8/22/2023

   The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.

6. Oligonucleotide Purification And Synthesis 1/27/2026

   Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.

7. Potent Immune Response With Vernal's LNP-mRNAs 4/26/2024

   As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality.

8. Leveraging Single-Use Technology For mRNA-LNP Drug Manufacturing 6/12/2023

   Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.

9. Current Challenges In The Plasmid DNA Manufacturing Process 4/24/2026

   PolyA tail stability shapes mRNA potency, consistency, and manufacturability. Addressing integrity early reduces variability, simplifies workflows, and supports reliable clinical scale‑out.

10. The Critical Bottleneck In Personalized Cancer Vaccines 6/19/2026

    Personalized cancer vaccines face a DNA production bottleneck. Synthetic approaches speed timelines, boost consistency, and simplify workflows to deliver individualized therapies faster.